MARRONE BIO INNOVATIONS INC

Form 4 March 05, 2014

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or Form 5

may continue.

SECURITIES obligations

See Instruction 1(b).

(Last)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Glidewell Donald J

(First)

2. Issuer Name and Ticker or Trading Symbol

MARRONE BIO INNOVATIONS INC [MBII]

3. Date of Earliest Transaction (Month/Day/Year)

03/03/2014

5. Relationship of Reporting Person(s) to

Issuer

below)

(Check all applicable)

CFO and Secretary

10% Owner

Other (specify

OMB

Number:

Expires:

response...

OMB APPROVAL

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

C/O MARRONE BIO INNOVATIONS, INC., 2121

SECOND STREET, STE. A-107

(Middle)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

Director

X_ Officer (give title

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

DAVIS, CA 95618

(City)	(State) (Zip) Tabl	e I - Non-D	erivative	Secur	rities Acq	uired, Disposed o	f, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securi or(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/03/2014		M	1,992	A	\$ 1.19	1,992	D	
Common Stock	03/03/2014		S(4)	1,992	D	\$ 14.86 (5)	0	D	
Common Stock	03/03/2014		M	265	A	\$ 1.41	265	D	
Common Stock	03/03/2014		S(4)	265	D	\$ 14.86	0	D	

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

					(5)	
Common Stock	03/03/2014	M	664	A	\$ 6.28 664	D
Common Stock	03/03/2014	S(4)	664	D	\$ 14.86 0 (5)	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

8. I De Sec (In

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number on f Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.19	03/03/2014		M	1,992	<u>(1)</u>	04/27/2021	Common Stock	1,992
Stock Option (Right to Buy)	\$ 1.41	03/03/2014		M	265	(2)	12/15/2021	Common Stock	265
Stock Option (Right to Buy)	\$ 6.28	03/03/2014		M	664	(3)	05/11/2022	Common Stock	664

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
			CFO and Secretary				

Reporting Owners 2

Edgar Filing: MARRONE BIO INNOVATIONS INC - Form 4

Glidewell Donald J C/O MARRONE BIO INNOVATIONS, INC. 2121 SECOND STREET, STE. A-107 DAVIS, CA 95618

Signatures

/s/ Donald J. 03/04/2014 Glidewell

**Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests with respect to 1/4th of the total shares subject to the option on the first anniversary of the vesting commencement date of May 1, 2011, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (2) The options vest with respect to 1/60th of the total shares subject to the option one month after the vesting commencement date of November 1, 2011, and with respect to 1/60th of the total shares subject to the option monthly thereafter for 36 months.
- (3) The option vests with respect to 1/4th of the total shares subject to the option on May 1, 2013, and with respect to 1/48th of the total shares subject to the option monthly thereafter for 36 months.
- (4) The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 Sales Plan adopted by the Reporting Person on December 13, 2013.

The transaction was executed in multiple trades and the price reported above reflects the weighted average purchase price. The Reporting (5) Person hereby undertakes to provide upon request to the SEC Staff, the Issuer or the Security Holder of the Issuer, full information regarding the number of shares and prices at which each trade was effected.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3